PT  - JOURNAL ARTICLE
AU  - Qasmieh, Saba A
AU  - Robertson, McKaylee M
AU  - Teasdale, Chloe A
AU  - Kulkarni, Sarah G
AU  - Nash, Denis
TI  - Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022
AID  - 10.1101/2022.04.23.22274214
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.23.22274214
4099  - http://medrxiv.org/content/early/2022/04/27/2022.04.23.22274214.short
4100  - http://medrxiv.org/content/early/2022/04/27/2022.04.23.22274214.full
AB  - In a population-based survey of NYC adults, we assessed positive SARS-CoV-2 tests (including via exclusive at-home testing) and possible cases among untested respondents. An estimated 27.4% (95%CI: 22.8%-32.0%) or 1.8 million adults (95%CI: 1.6-2.1 million) had SARS-CoV-2 infection. SARS-CoV-2 prevalence was high among groups that are more vulnerable to severe SARS-CoV-2 and death, including unvaccinated persons (21.7%, 95%CI 9.6%-33.8%) and those aged 65+ (17.8%, 95%CI 10.2-25.4%). Population-based representative surveys are an important adjunct surveillance tool to standard testing-based SARS-CoV-2 surveillance.Competing Interest StatementNash, Kulkarni, and Robertson have received COVID-19 research finding from Pfizer for a separate project.Funding StatementFunding for this project was provided by the CUNY Institute for Implementation Science in Population Health (cunyisph.org).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Institutional Review Board at the City University of New York (CUNY).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.